Role of miR-506 in ulcerative colitis associated with primary sclerosing cholangitis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
12 05 2021
Historique:
received: 25 02 2021
accepted: 26 04 2021
entrez: 13 5 2021
pubmed: 14 5 2021
medline: 29 10 2021
Statut: epublish

Résumé

Primary sclerosing cholangitis (PSC) is commonly accompanied by ulcerative colitis (UC). MicroRNA-506 modulates expression of genes which are essential for sphingosine-mediated signaling pathway and intestinal mucosa protection. We investigated whether miR-506 and its target genes are involved in phenotypic presentations of colonic inflammation and/or neoplasia. We analyzed serum and colon tissue samples collected from patients with PSC, PSC with concurrent UC (PSC + UC), UC alone, and healthy controls (n = 10 each). MiR-506 was substantially upregulated in ascending colons of PSC and PSC + UC patients, in contrast to sigmoid colons of PSC and UC patients. Upregulation of miR-506 was associated with inhibition of SPHK1, AE2, InsP3R3, and p53. Colonic suppression of miR-506 presented in UC was accompanied by substantially increased DNMT1, SPHK1, and S1P lyase expressions. A functional in vitro analysis in Caco-2 cells showed that the induction of miR-506 activity by miR-506 mimic or GDCDA bile acid suppressed, whereas inhibition of miR-506 by miR-506 inhibitor or lipopolysaccharide (LPS) upregulated the expression of the examined target genes. A different phenotypic presentation of colitis may be related to miR-506 expression. In ascending colons with PSC + UC, upregulation of miR-506 may result in failure of bicarbonate secretion and inhibition of p53, which predisposes to pro-tumorigenic transformation. In contrast, downregulation of miR-506 enhances S1P production, leading to pro-inflammatory signaling.

Identifiants

pubmed: 33980925
doi: 10.1038/s41598-021-89631-4
pii: 10.1038/s41598-021-89631-4
pmc: PMC8114918
doi:

Substances chimiques

Biomarkers 0
MIRN506 microRNA, human 0
MicroRNAs 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10134

Références

Trends Cell Biol. 2012 Jan;22(1):50-60
pubmed: 22001186
Hepatology. 2012 Aug;56(2):687-97
pubmed: 22383162
Oncotarget. 2015 Nov 10;6(35):38139-50
pubmed: 26497367
Oncogene. 2015 Feb 5;34(6):691-703
pubmed: 24469051
Oncotarget. 2016 Mar 1;7(9):10322-31
pubmed: 26862732
Cancer Res. 2016 Jul 1;76(13):3666-70
pubmed: 27325641
World J Surg Oncol. 2014 May 24;12:164
pubmed: 24884764
Cell Calcium. 2020 Jan;85:102132
pubmed: 31790953
Hepatology. 2018 Apr;67(4):1420-1440
pubmed: 28922472
Nat Rev Urol. 2018 Apr;15(4):222-234
pubmed: 29460925
Oncotarget. 2016 Sep 20;7(38):62778-62788
pubmed: 27542202
Curr Biol. 2000 Nov 30;10(23):1527-30
pubmed: 11114522
J Clin Invest. 2014 Dec;124(12):5368-84
pubmed: 25347472
Lancet. 2013 Nov 9;382(9904):1587-99
pubmed: 23810223
Cancer. 1982 Aug 1;50(3):543-7
pubmed: 7093895
J Biol Chem. 2015 Jan 2;290(1):184-96
pubmed: 25378392
Science. 1997 Mar 28;275(5308):1943-7
pubmed: 9072974
Toxicol Appl Pharmacol. 2012 Oct 1;264(1):13-22
pubmed: 22841775
Cancer Res. 2009 Sep 15;69(18):7412-21
pubmed: 19723660
Curr Drug Targets. 2008 Aug;9(8):662-73
pubmed: 18691013
Gastroenterology. 2017 Jun;152(8):1975-1984.e8
pubmed: 28274849
Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):170-7
pubmed: 23325473
Cancer Res. 2007 Aug 15;67(16):7773-81
pubmed: 17699782
Oncogene. 2016 Oct 20;35(42):5501-5514
pubmed: 27065335
Nat Rev Cancer. 2010 Jul;10(7):489-503
pubmed: 20555359
Liver Int. 2013 Feb;33(2):231-8
pubmed: 23295054
Inflamm Bowel Dis. 2009 Sep;15(9):1331-6
pubmed: 19229982
Cancer Res. 2009 Dec 15;69(24):9346-53
pubmed: 19934311
Clin Rev Allergy Immunol. 2020 Feb;58(1):25-38
pubmed: 30900136
J Biol Chem. 2004 Jan 9;279(2):1281-90
pubmed: 14570870
Oncotarget. 2015 Oct 20;6(32):32586-601
pubmed: 26452129
Hepatology. 2012 Jan;55(1):173-83
pubmed: 21932391
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17384-9
pubmed: 17090686

Auteurs

Agnieszka Kempinska-Podhorodecka (A)

Department of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland. agnieszkakempinska@interia.eu.

Monika Adamowicz (M)

Department of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.

Ewa Ostrycharz (E)

Department of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.

Mateusz Chmielarz (M)

Department of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.

Maciej Wójcicki (M)

Liver and Internal Medicine Unit, Medical University of Warsaw, 02-097, Warsaw, Poland.
European Reference Network (ERN) Rare-Liver, Warsaw, Poland.

Piotr Milkiewicz (P)

Liver and Internal Medicine Unit, Medical University of Warsaw, 02-097, Warsaw, Poland.
European Reference Network (ERN) Rare-Liver, Warsaw, Poland.
Translational Medicine Group, Pomeranian Medical University, 70-111, Szczecin, Poland.

Malgorzata Milkiewicz (M)

Department of Medical Biology, Pomeranian Medical University, 70-111, Szczecin, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH